# CoGenesys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/cogenesys

- Industry: Pharmaceuticals
- Headquarters: Rockville, US
- Website: www.cogenesys.com
- Total disclosed funding: $55M
- Latest round: Series A (Jun 12, 2006)
- Investors on record: 4

## About

CoGenesys is focused on delivering advanced cloud-based solutions that enhance operational efficiency for businesses across various sectors, catering to both small and large enterprises with tailored offerings.CoGenesys specializes in developing innovative technology solutions. The company is headquartered in Rockville, US. Afizat Ismail serves as the CEO. The most recent funding round was a TRADE SALE amounting to USD 400.000 mn led by Teva Pharmaceutical Industries, marking the total amount raised to USD 400.000 mn. The company has engaged in 2.0 deals since its establishment.CoGenesys.com is preparing to launch a range of innovative products and services designed to address specific market needs within the technology sector. The core offerings include advanced cloud-based solutions that streamline operations for businesses across various industries, enhancing productivity and efficiency. These products target small to medium-sized enterprises (SMEs) and larger corporations, providing tailored solutions that integrate seamlessly into existing systems. Anticipated end use cases involve improved data management, enhanced collaboration tools, and increased operational transparency, with a focus on markets in North America, Europe, and parts of Asia.The revenue model for CoGenesys.com is structured around subscription-based services and B2B partnerships, allowing clients to access their offerings on a recurring basis. Each subscription tier meets varying user needs, enabling companies to select the most appropriate plan based on their operational scale and requirements. Clients engage in direct contracts for services provided, ensuring a consistent revenue stream. Flagship products, once launched, will likely include specialized software solutions tailored to specific industry needs, significantly contributing to the overall revenue structure.CoGenesys is actively designing and preparing to launch new products targeted for release soon after the TRADE SALE on January 22, 2008. The company plans to expand into North America, Europe, and parts of Asia by the end of 2023. The funding from the recent TRADE SALE will be utilized to support these product launches and geographic expansions.

## Funding rounds

- Series A, Jun 12, 2006, $55M — New Enterprise Associates, OrbiMed Advisors, Red Abbey, Human Genome Sciences, Inc.

## Investors

- New Enterprise Associates (https://capitalatlas.ai/funds/new-enterprise-associates) — Series A
- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A
- Red Abbey (https://capitalatlas.ai/funds/red-abbey) — Series A
- Human Genome Sciences, Inc. — Series A